ESR1 and breast cancer: In this regard, compared to control groups of breast cancer as the only malignancy, the expression of both ER and progesterone receptor (PR) was found to be significantly increased in breast cancer specimens from women who also had DTC, regardless of which of the two cancers had occurred first and/or of the latency to detection of the second malignancy (90, 91).